Immunome (NASDAQ:IMNM) Hits New 12-Month Low – Time to Sell?

Immunome, Inc. (NASDAQ:IMNM) shares reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $8.51 and last traded at $8.88, with a volume of 395083 shares changing hands. The stock had previously closed at $9.34.

Analysts Set New Price Targets

IMNM has been the topic of a number of research reports. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Monday. Piper Sandler lowered their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $28.60.

Immunome Trading Down 5.2 %

The company has a market capitalization of $706.03 million, a price-to-earnings ratio of -1.09 and a beta of 1.93. The firm’s 50-day moving average price is $10.15 and its 200 day moving average price is $11.98.

Insider Activity

In other Immunome news, CEO Clay B. Siegall acquired 150,000 shares of Immunome stock in a transaction that occurred on Friday, January 31st. The shares were acquired at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the purchase, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at $5,189,679. This represents a 28.87 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

A number of hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets bought a new stake in shares of Immunome during the fourth quarter worth $70,000. KLP Kapitalforvaltning AS bought a new position in Immunome in the fourth quarter valued at about $75,000. AlphaQuest LLC grew its holdings in shares of Immunome by 786,700.0% during the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after purchasing an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company’s stock valued at $91,000 after buying an additional 7,129 shares during the period. Finally, Aquatic Capital Management LLC acquired a new stake in Immunome during the 4th quarter worth approximately $95,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.